BARCELONA — Adding lenvatinib and pembrolizumab to transarterial chemoembolization (TACE) led to a significant improvement in progression-free survival in patients with intermediate-stage hepatocellular carcinoma compared with TACE plus placebo, according to findings from the first interim analysis of the phase 3 LEAP-012 study. The results, presented here at the European Society for Medical Oncology…
